Article Id:JPRS-PCS-00001584 Title:Formulation of olmesartan medoxomil nanoparticulate drug delivery for enhancement of oral bioavailability by Ionic-Gelation Techniques Category:Pharmaceutics Section:Research Article
Abstract
Audio Abstract
Authors
Pdf File
Citation
My Reference
Methodology
Abstract
The drug olmesartan medoxamil bioavailability is only 26% due to its poor aqueous solubility. The purpose of this study is to improve aqueous solubility by nanotechnology of Ionicgelation technique using chitosan as polymer and tripoly phosphate as cross linking agent. The nanoparticles of olmeasartan medoxamil is formulated to increase oral bioavailability by preparing particles of nano size range with good zeta potential and SEM analysis of prepared particle is done to confirm the surface morphology of nanoparticles with free of clusters. The different formulation of olmesartan medoxomil nanoparticles were compressed into tablets and it complies with IP standard for tablet. In-vitro release study of all the formulation were done to confirms its enhancement of in-vitro bioavailability, when compare to marketed formulation-M of 93 ± 2.95% drug release at 60 minutes, formulation OLM-9 of nanoparticle has shown 99% at 20 minutes with particle size of 633 nm, which indicates 3 fold increase in the in-vitro dissolution rate of olmesartan medoxomil. The prepared particles were free from clusters and with good zeta potential.
Abstract Audio
No Audio file found
About the authors and Affiliations
Name
JPR Solutions
Author(s) Name:
Subramanian Somaskandan*1, Ravichandran Swaminathan2, Kavi Arasu Muthukuamraswamy1 , Mohammad Abdul Shareef1,
Affiliation(s) Name:
1 Department of pharmaceutics, PSG College of Pharmacy, Coimbatore - 641004 , Tamilnadu, India. 2. Department of pharmaceutical analysis, PSG College of Pharmacy, Coimbatore - 641004 , Tamilnadu, India.
*Corresponding author. Subramanian.S Associate Professor, Department of pharmaceutics, PSG College of Pharmacy, Coimbatore - 641004, Tamilnadu, India.
Received on:21-06-2014; Revised on: 19-07-2014; Accepted on:04-08-2014